Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Deciphera Pharmaceuticals Inc's Business Segments
Deciphera Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 163
Regions Reported
-
Deciphera Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product94.6%
- Collaboration Arrangement5.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 43 | 94.6% |
| Collaboration Arrangement | $ 2 | 5.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc is a biopharmaceutical company that is focused on discovering, developing, and commercializing kinase inhibitor therapies for the treatment of patients with cancer. The company was established in 2003 and is based in Waltham, Massachusetts.
The core technology of Deciphera Pharmaceuticals is its proprietary kinase switch control inhibitor platform (KSCI). This technology enables the company to design highly selective inhibitors that target specific kinases and to optimize the molecules with respect to potency, safety, and pharmacokinetics.
The company's lead product candidate is Ripretinib (DCC-2618), an inhibitor of KIT and PDGFRα kinases that is being evaluated for the treatment of patients with gastrointestinal stromal tumors (GISTs). GISTs are rare cancerous tumors that arise in the digestive tract and account for approximately 1% of all gastrointestinal tumors.
In addition to Ripretinib, Deciphera Pharmaceuticals has a pipeline of early-stage product candidates that are being developed for the treatment of a variety of solid tumor indications. These include inhibitors of kinases such as FGFR, CSF1R, and VEGFR.
Deciphera Pharmaceuticals has collaborated with several pharmaceutical companies, including Eli Lilly and Company, Sanofi, and Takeda Pharmaceutical Company Limited, to develop and commercialize its product candidates. The company has also entered into licensing agreements with other companies to further develop its KSCI platform and expand its product portfolio.
The company has received several awards and recognitions for its innovative technology and drug development efforts. In 2019, Deciphera Pharmaceuticals was named one of the top 50 most innovative companies in the world by Fast Company. The company is also listed on the NASDAQ Global Select Market under the ticker symbol "DCPH."
The core technology of Deciphera Pharmaceuticals is its proprietary kinase switch control inhibitor platform (KSCI). This technology enables the company to design highly selective inhibitors that target specific kinases and to optimize the molecules with respect to potency, safety, and pharmacokinetics.
The company's lead product candidate is Ripretinib (DCC-2618), an inhibitor of KIT and PDGFRα kinases that is being evaluated for the treatment of patients with gastrointestinal stromal tumors (GISTs). GISTs are rare cancerous tumors that arise in the digestive tract and account for approximately 1% of all gastrointestinal tumors.
In addition to Ripretinib, Deciphera Pharmaceuticals has a pipeline of early-stage product candidates that are being developed for the treatment of a variety of solid tumor indications. These include inhibitors of kinases such as FGFR, CSF1R, and VEGFR.
Deciphera Pharmaceuticals has collaborated with several pharmaceutical companies, including Eli Lilly and Company, Sanofi, and Takeda Pharmaceutical Company Limited, to develop and commercialize its product candidates. The company has also entered into licensing agreements with other companies to further develop its KSCI platform and expand its product portfolio.
The company has received several awards and recognitions for its innovative technology and drug development efforts. In 2019, Deciphera Pharmaceuticals was named one of the top 50 most innovative companies in the world by Fast Company. The company is also listed on the NASDAQ Global Select Market under the ticker symbol "DCPH."
Deciphera Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for patients with cancer and other life-threatening diseases. The companys activities are primarily concentrated in the United States, where it is advancing several product candidates through clinical trials with a commitment to enhancing treatment options for patients.
Segments:
Deciphera Pharmaceuticals operates within one primary segment: the development and commercialization of targeted therapies aimed at treating cancer and other severe health conditions. This singular focus allows the company to concentrate its resources and expertise on refining and advancing its drug candidates through various phases of clinical development.
Products and Services:
1. Ripretinib:
- Overview: Ripretinib is an oral small molecule kinase inhibitor specifically designed to target certain mutant forms of the KIT protein, as well as other related pathways involved in the progression of gastrointestinal stromal tumors (GIST).
- Indications: The primary indication for Ripretinib is GIST, particularly in patients who have received prior therapies based on imatinib.
- Regulatory Status: The drug has currently undergone FDA review and has been granted Fast Track Designation, facilitating accelerated approval processes based on promising early results.
2. DCC-3014:
- Overview: DCC-3014 is a targeted kinase inhibitor that inhibits the colony-stimulating factor 1 receptor (CSF1R). This receptor is pivotal in the creation and activation of tumor-associated macrophages (TAMs), which often contribute to tumor growth and immune evasion.
- Indications: Early studies indicated potential applications in various cancers, particularly those characterized by robust TAM infiltration.
- Clinical Trials: DCC-3014 is under investigation for use in various malignancies, where modulating the tumor microenvironment could yield therapeutic benefits.
3. DCC-3116:
- Overview: This compound is formulated as a selective inhibitor targeting mutations in the FLT3 kinase, which is frequently mutated in acute myeloid leukemia (AML) and is associated with poor prognosis.
- Indications: DCC-3116 is being explored primarily in the context of AML treatment, where it aims to inhibit the pathway activated by FLT3 mutations and restore more effective cellular apoptosis.
- Clinical Development: The drug is expected to provide a treatment advantage for patients who harbor FLT3 mutations and have limited options after first-line therapies.
4. DCC-3018:
- Overview: Similar to DCC-3014, DCC-3018 is a kinase inhibitor targeting CSF1R, aiming to address rare diseases characterized by abnormal immune system activation due to CSF1R dysregulation.
- Indications: This drug candidate has potential therapeutic applications in conditions where the CSF1R pathway is implicated in pathogenesis, suggesting a narrower but critical applicability in rare disorders.
- Research Focus: DCC-3018 is undergoing early clinical trials aimed at understanding its efficacy and safety profile in the target patient populations.
Clinical Services:
Deciphera Pharmaceuticals also provides clinical services aimed at facilitating access to clinical trials for patients battling cancer and other life-threatening conditions. These clinical services are integral in offering:
- Patient Education and Support: Deciphera proactively supports patients by guiding them through the complexities of the clinical trial process, ensuring they are informed about potential benefits and risks.
- Trial Navigation: Patients receive personalized assistance in identifying suitable clinical trials and understanding the enrollment criteria, which can often be overwhelming.
- Risk-Benefit Discussions: The company emphasizes clear communication regarding the expected outcomes and limitations of participation in trials, thus ensuring that patients are empowered to make informed decisions regarding their treatment options.
In summary, Deciphera Pharmaceuticals Inc. is dedicated to developing innovative therapies and providing essential support services to enhance the treatment landscape for patients suffering from cancer and related diseases. Their focus on targeted therapies represents a significant advancement in precision medicine, with the potential to notably improve patient outcomes.
Segments:
Deciphera Pharmaceuticals operates within one primary segment: the development and commercialization of targeted therapies aimed at treating cancer and other severe health conditions. This singular focus allows the company to concentrate its resources and expertise on refining and advancing its drug candidates through various phases of clinical development.
Products and Services:
1. Ripretinib:
- Overview: Ripretinib is an oral small molecule kinase inhibitor specifically designed to target certain mutant forms of the KIT protein, as well as other related pathways involved in the progression of gastrointestinal stromal tumors (GIST).
- Indications: The primary indication for Ripretinib is GIST, particularly in patients who have received prior therapies based on imatinib.
- Regulatory Status: The drug has currently undergone FDA review and has been granted Fast Track Designation, facilitating accelerated approval processes based on promising early results.
2. DCC-3014:
- Overview: DCC-3014 is a targeted kinase inhibitor that inhibits the colony-stimulating factor 1 receptor (CSF1R). This receptor is pivotal in the creation and activation of tumor-associated macrophages (TAMs), which often contribute to tumor growth and immune evasion.
- Indications: Early studies indicated potential applications in various cancers, particularly those characterized by robust TAM infiltration.
- Clinical Trials: DCC-3014 is under investigation for use in various malignancies, where modulating the tumor microenvironment could yield therapeutic benefits.
3. DCC-3116:
- Overview: This compound is formulated as a selective inhibitor targeting mutations in the FLT3 kinase, which is frequently mutated in acute myeloid leukemia (AML) and is associated with poor prognosis.
- Indications: DCC-3116 is being explored primarily in the context of AML treatment, where it aims to inhibit the pathway activated by FLT3 mutations and restore more effective cellular apoptosis.
- Clinical Development: The drug is expected to provide a treatment advantage for patients who harbor FLT3 mutations and have limited options after first-line therapies.
4. DCC-3018:
- Overview: Similar to DCC-3014, DCC-3018 is a kinase inhibitor targeting CSF1R, aiming to address rare diseases characterized by abnormal immune system activation due to CSF1R dysregulation.
- Indications: This drug candidate has potential therapeutic applications in conditions where the CSF1R pathway is implicated in pathogenesis, suggesting a narrower but critical applicability in rare disorders.
- Research Focus: DCC-3018 is undergoing early clinical trials aimed at understanding its efficacy and safety profile in the target patient populations.
Clinical Services:
Deciphera Pharmaceuticals also provides clinical services aimed at facilitating access to clinical trials for patients battling cancer and other life-threatening conditions. These clinical services are integral in offering:
- Patient Education and Support: Deciphera proactively supports patients by guiding them through the complexities of the clinical trial process, ensuring they are informed about potential benefits and risks.
- Trial Navigation: Patients receive personalized assistance in identifying suitable clinical trials and understanding the enrollment criteria, which can often be overwhelming.
- Risk-Benefit Discussions: The company emphasizes clear communication regarding the expected outcomes and limitations of participation in trials, thus ensuring that patients are empowered to make informed decisions regarding their treatment options.
In summary, Deciphera Pharmaceuticals Inc. is dedicated to developing innovative therapies and providing essential support services to enhance the treatment landscape for patients suffering from cancer and related diseases. Their focus on targeted therapies represents a significant advancement in precision medicine, with the potential to notably improve patient outcomes.